Break out session on Cancer 2024

This session is chaired by:  Dr. Linda Lindström, KI &  Dr. Thomas Witzig, Mayo clinic

• 10-10:25 am: Keynote Lecture: Dr. Aaron  Mansfield, Mayo Clinic
  Biomarker---Notch
   
• 10:30-10:55 am: Keynote Lecture: Dr. Urban Lendahl, Karolinska Institutet
  To be determined
   
• 11:00- 11:15 am: Human Epidermal growth factor Receptor 2 (HER2) PET imaging of HER2-low breast cancer with [68Ga]Ga-ABY-025: results from a pilot study
  Dr Renske Altena, Karolinska Institutet;Karolinska University Hospital
   
• 11:20-11:35 am: The ORF8 Monocyte Stimulation Test (OMST) - a New Assay of Monocyte Secretory Function
  Dr Thomas Witzig, Mayo Clinic
   
• 11:40-11:55 am: Enhancing Head and Neck Nodal Chain Contouring: AI Innovations in Adaptive Proton       Radiotherapy and Radiomics
      Dr Aman Anand, Mayo Clinic

Conference keynote lecture by Dr. Markus Lingman. Lingman is senior cardiologist, professor of medicine and chief strategy officer. 

Session chaired by Dr. Aaron Mansfield, Mayo Clinic & Dr. Elias Arnér, KI

• 2-2:15 pm: Comprehensive single cell analysis of the epigenome of ovarian cancer
  Dr Alexandre Gaspar Maia, Mayo Clinic
   
• 2:20-2:35 pm: Basic and translational studies on cancer-associated fibroblasts
  Dr Arne Östman, Karolinska Institutet
   
• 2:40 -2:55 pm: The contribution of tumor-macrophage interplay in the metastasis of neuroblastoma with LMO1 overexpression
  Dr Shizhen (Jane) Zhu, Mayo Clinic
• 3-3:15 pm: Modulating the regulators of immune checkpoints to improve the anti-tumor immune response in High-Grade Serous Ovarian Carcinoma
  Mr Mihai Dumbrava, Mayo Clinic
   
• 3:20-3:40 pm: Coffe break
   
• 3:40-3:55 pm: Novel Image Spatial Analysis Workflow Systematically Identifies Multiple Perivascular Marker-Defined Abnormal Vascular Structural Patterns with Prognostic and Macrophage Exudative Properties in CRC
  Dr Linglong Huang, Karolinska Institutet
   
• 4-4:15 pm: Investigating the Extracellular Vesicle Protein Cargo of Brain Tumor-Initiating Cells and Its Impact on the Tumor Microenvironment
  Ms Marissa Russo, Mayo Clinic

Chaired by: Dr. Andrea Wahner Hendrickson, Mayo Clinic & Dr. Ninib Baryawno, KI

• 4:20-4:35 pm: Tumor-derived microRNA, miR-125a, is elevated at baseline in CART nonresponders and induces CART cell dysfunction in B cell malignancies
  Dr Saad Kendrian (Ms Olivia Sirpilla), Mayo Clinic
   
• 4:40-4:55 pm: Impact of inhibition of the epigenetic regulator Enhancer of Zeste Homolog 2 in childhood medulloblastoma malignancy
  Mr Jiansheng Wang, Karolinska Institutet 

Chairs: Dr. Matt Goetz, Mayo Clinic and Dr. Renske Altena, Karolinska Institute

• 9:00-9:15 am: A long-term image-derived AI-based risk model for primary prevention of breast cancer
  Dr Mikael Eriksson, Karolinska Institutet
   
• 9.20-9:35 am: Cancer-Associated Fibroblast Precursors Exist Prior to Breast Cancer Development
   Dr Derek Radisky, Mayo Clinic
   
• 9.40-9:55 am: Determining the need for recalibration of three approved mammography AI CAD systems depending on the manufacturer of the mammography equipment.
  Dr Haiko Schurz, Karolinska Institutet
   
• 10-10:15 am: Risk of pancreatic cancer in first-degree relatives of individuals with precursors: a Swedish nationwide cohort study
  Dr Qiaoli Wang, Karolinska Institutet
   
• 10:20-10:35 am: Biological Tumor Traits Predicting Late Recurrence in Premenopausal Breast Cancer Patients – Insights from the STO-5 trial with 20-year follow-up
  Mr Jo De Vos, Karolinska Institutet
   
• 10:40-11 am: Coffee break
   
• 11-12 am: Panel discussions
   

• 2:30-2:45 pm: Loss of CDK2 induces neuronal differentiation in human neuroblastoma
  Dr Mohammad Alzrigat, Karolinska Institutet
   
• 2:50-3:05 pm: Deciphering the mechanism of methionine dependency in cancer
  Mohamed Elhusseiny, Karolinska Institutet
   
• 3:10-3:25 pm: Non-invasive circulating tumor DNA genomic analyses for diagnosis and monitoring of treatment response in lymphoma
  Dr Zahra Haider Karolinska Institutet;Karolinska University Hospital
   
• 3:30-3:50 pm: Coffee break
   
• 3:50-4:05 pm: Subgroup analyses from the randomized PANTHER trial on adjuvant tailored dose dense chemotherapy for high-risk early breast cancer
  Dr Alexios Matikas Karolinska Institutet;Karolinska University Hospital
   
• 4:10-4:25 pm: Differential Long-term Benefit from 2-Year Adjuvant tamoxifen Therapy for Luminal-Type Breast Cancer of High and Low-risk: Insights from a 20-Year Follow-Up Analysis of the STO Trials
  Dr Magdalena Ríos Romero, Karolinska Institutet
   
• 4:30-4:45 pm: Gene expression landscape of long-term tamoxifen resistance in premenopausal ER+ breast cancer
  Dr Julia Tutzauer, Karolinska Institutet